A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

May 27, 2026 updated by: Merck Sharp & Dohme LLC

A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history or presence of clinically significant medical or psychiatric condition or disease
  • Has a history of cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MK-7262
Participants will receive MK-7262 orally.
Drug: MK-7262
Oral administration
Experimental: Enlicitide
Participants will receive enlicitide orally.
Drug: Enlicitide
Oral administration
Other Names:
  • MK-0616
  • enlicitide decanoate
Experimental: MK-7262 plus Enlicitide
Participants will receive MK-7262 and enlicitide orally.
Drug: Enlicitide
Oral administration
Other Names:
  • MK-0616
  • enlicitide decanoate
Drug: MK-7262
Oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days)
Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.
Predose and at designated time points post-dose (up to 8 days)
AUC0-inf of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
Maximum Plasma Concentration (Cmax) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
Cmax of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.
Predose and at designated time points post-dose (up to 24 hours post-dose)
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
Time to Maximum Plasma Concentration (Tmax) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Terminal Half-life (t1/2) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the t1/2 of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Clearance (CL/F) of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the CL/F of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Volume of Distribution During Terminal Phase (Vz/F)of MK-7262
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the Vz/F of MK-7262.
Predose and at designated time points post-dose (up to 8 days post-dose)
AUC0-24 of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.
Predose and at designated time points post-dose (up to 24 hours post-dose)
AUC0-last of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
Tmax of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
t1/2 of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the t1/2 of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
CL/F of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the CL/F of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
Vz/F of Enlicitide
Time Frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Blood samples will be collected at multiple time points to estimate the Vz/F of enlicitide.
Predose and at designated time points post-dose (up to 8 days post-dose)
Number of Participants Who Experience One or More Adverse Events (AEs)
Time Frame: Up to approximately 8 weeks
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.
Up to approximately 8 weeks
Number of Participants Who Discontinue Study Due to an AE
Time Frame: Up to approximately 6 weeks
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.
Up to approximately 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Merck Sharp & Dohme LLC

Investigators

  • Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 6, 2026

Primary Completion (Estimated)

September 5, 2026

Study Completion (Estimated)

September 12, 2026

Study Registration Dates

First Submitted

May 27, 2026

First Submitted That Met QC Criteria

May 27, 2026

First Posted (Actual)

June 2, 2026

Study Record Updates

Last Update Posted (Actual)

June 2, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7262-003
  • MK-7262-003 (Other Identifier: MSD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Enlicitide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe